Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.74
0.00 (0.00%)
Sep 15, 2025, 4:00 PM EDT - Market closed
Arvinas Revenue
Arvinas had revenue of $22.40M in the quarter ending June 30, 2025, a decrease of -70.72%. This brings the company's revenue in the last twelve months to $372.80M, up 299.57% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$372.80M
Revenue Growth
+299.57%
P/S Ratio
1.50
Revenue / Employee
$866,977
Employees
430
Market Cap
568.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARVN News
- 6 days ago - Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 17 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer - GlobeNewsWire
- 5 weeks ago - Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 2 months ago - Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - GlobeNewsWire
- 3 months ago - Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress - GlobeNewsWire